suMMARY An open study of long term treatment with an oral beta2 agonist (pirbuterol 20 mg three times daily) was undertaken in 63 patients with severe chronic heart failure. During three months of treatment 20 (32%) patients died, of whom 16 were taking the drug at the time of death. Mortality was related to initial functional class (New York Heart Association classification: 23% in grade III and 75% in grade IV). Concomitant treatment with digoxin did not affect mortality. The drug was well tolerated by most patients but unwanted side effects necessitated withdrawal of the drug in six (10%). Thirty-five patients were continuing to take the drug after three months, of whom 22 reported symptomatic improvement and only four deterioration. There was a relation between symptomatic improvement and increase in exercise capacity. At initial haemodynamic assessment a single dose of pirbuterol increased the cardiac index by 34% and the stroke index by 21%. Left ventricular filling pressure fell by 23% and systemic vascular resistance by 22%. Haemodynamic reassessment after three months of continuous treatment in 29 patients showed maintained improvement in the group as a whole, although individual variation was considerable. There was no apparent relation between haemodynamic improvement and improvement in exercise duration and symptoms.
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Severe heart failure has a poor prognosis. Identification of those patients who may derive benefit from treatment with a particular drug is not yet possible.
Severe chronic heart failure refractory to conventional treatment with diuretics and digitalis remains a major therapeutic problem. That vasodilator drugs in this group of patients produce acute haemodynamic benefit is well established'-9 but the clinical benefits of long term treatment with many of these agents are less certain and the natural history of the condition has not been shown to be altered. Some reports show sustained clinical and haemodynamic benefit2 4-69-11 but others do not, and haemodynamic tolerance develops in a proportion of patients treated with hydralazine,3 prazosin,2 13 and isosorbide dinitrate. '4 One uniform characteristic of these disparate reports is the small number of patients that comprise the study groups.
In this paper we report the results of an open study Accepted for publication 7 June 1983 in a large series of 63 patients with severe chronic heart failure treated long term with pirbuterol, a drug currently marketed in Britain for the treatment of asthma. Pirbuterol is a beta2 adrenergic agonist with both vasodilator and positive inotropic properties. 15 Patients and methods 
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Results
ACUTE RESPONSE
The initial acute haemodynamic responses to pirbuterol in the 63 patients who entered the study are shown in Table 1 and Fig. 1 . The results represent values for control and peak response. Cardiac index and stroke volume index were both increased (p<0-001). Left ventricular filling pressure and calculated systemic vascular resistance were reduced (p<0.001). Heart rate and systolic blood pressure were unchanged but there was a reduction in diastolic blood pressure (p<0-01). Thirty five of the 63 patients entering the study were still receiving pirbuterol after three months. During this period concomitant diuretic treatment was unaltered in 18 patients, increased in 11 to combat symptoms of fluid retention, and reduced in six who developed clinical evidence of overdiuresis. Table 3 shows the relation between alteration in clinical status and alteration in diuretic treatment.
Of those 18 patients in whom treatment was unaltered, 14 (78%) reported symptomatic improvement and none symptomatic deterioration. In the group of 35 patients overall, 22 reported symptomatic improvement, nine no change, and four symptomatic deterioration. All of the patients in whom there was symptomatic deterioration belonged to the subset in whom diuretics needed to be increased (Table 3) .
EXERCISE TESTS Thirty one of the 35 patients completing three months' treatment with pirbuterol had exercise tests before starting treatment and after three months. Exercise duration was increased in 23 (74%) patients, decreased in seven (23%), and unchanged in one. The mean (+ SEM) duration of exercise increased from 151+±21 s to 281+49 s (p<O0001). Fig. 2 summarises the results when the 31 patients are sepaated into Table 4 and Fig. 3 show the results for the group overall; the values given are dhe control and peak response in the initial study and immediately before and three hours after a 20 mg dose of pirbuterol in the long term study. The values before and after a scheduled dose after three months' treatment showed that haemodynamic benefit was maintained compared with the control response in the initial study. The concentration of pirbuterol at the time of the first measurement at three months was 18 ng/ml above that required for maximal haemodynamic response. For this reason the scheduled dose of pirbuterol did not bring about any further haemodynamic improvement.
The initial response to oral pirbuterol varied widely between patients, some showing little or no increase in cardiac index (Fig. 1) . Similar variation was found in other haemodynamic variables. Fig. 4 shows the relation between the initial peak response (assessed as increase in cardiac index) and the response after a routine maintenance dose after three months' treatment with pirbuterol (increase in cardiac index compared with the initial control value). In general, the initial response did not allow prediction of the long term response. Fig. 5 shows that in the 25 patients in whom both exercise and haemodynamic data were available there was only a tenuous relation (r=029) between haemodynamic improvement and improvement in exercise duration. Separation into subgroups dependent on whether or not diuretic treatment was increased (n=6), decreased (n=4), or unchanged (n=15, r=0-30) during the study period did not improve the relation (Fig. 5) . Furthermore, Fig. 5 shows that for the whole group of 25 patients or for the subgroups there was no simple relation between haemodynamic change (as measured by alteration in stroke volume index) and change in the patients' symptoms. experience of the acute haemodynamic response to oral pirbuterol in patients with heart failure16 17 prompted us to proceed to an open long term study of the drug.
In our study population the mortality rate at three months was 32%. Although it is conceivable that the drug had a deleterious effect, because agents with positive inotropic properties may adversely affect survival by promoting myocardial ischaemia or cell damage, we think that this is unlikely. Similar mortality rates have been reported in groups of patients with heart failure treated with vasodilator drugs such as hydralazine2l and prazosin.2 Furthermore, it is known that pirbuterol does not increase myocardial oxygen consumption in patients at rest,23 reduce plasma potassium concentration when given chronically,24 or increase the frequency of arrhythmias.24 The high mortality in our study probably reflects the extreme severity of disease in this population rather than any adverse effect of pirbuterol, an interpretation consistent with the observation that most deaths occurred in those patients categorised in grade IV (New York Heart Association.functional class)-that is, patients with the worst pump function and lowest cardiac reserve. This suggests that patients with grade IV symptoms are unsuitable for inclusion in long term drug trials designed to assess symptomatic response rather than mortality because the very high mortality rate (75% in three months) will inevitably confuse the interpretation of the results. Mortality was not affected by the simultaneous administration of digoxin and pirbuterol. In patients receiving digoxin and pirbuterol the three month mortality was 36%/a and with pi;r'uterol alone it was 27%, but a greater proportion of patients taking digoxin had grade IV symptoms.
Pirbuterol was well tolerated by most patients. Unwanted effects, principally tremor and muscle cramp, were reported by 12 patients and resulted in withdrawal from treatment in six (10%).
Diuretic treatment and salt intake were not rigidly controlled in this study. It is not feasible to do so in a large long term study of unselected patients with severe heart failure since some will deteriorate inexorably, requiring increasing diuretic dosage, while others may respond so well to treatment that failure to reduce diuretic dosage may result in overdiuresis and symptomatic deterioration. Of the 35 patients completing three months' treatment with pirbuterol, diuretic treatment was unchanged in 18. These 18 patients comprised a subgroup in whom changes in symptomatic status can reasonably be assumed to be due to drug effect. Fourteen (78%) of these patients reported symptomatic improvement and none symptomatic deterioration. In the group of 35 patients pverall, only 22 Dawson, Canepa-Anson, Kuan, Reuben, Poole-Wilson, Sutton Naughton protocols the additional exercise time is at a higher workload. Because of the study design both a training and a placebo effect may have contributed to the observed increase in exercise duration. Fig. 2 shows that the greatest increases in exercise duration tended to occur in those patients in whom diuretic treatment was unchanged or decreased and also that there was a relation between increase in exercise duration and reported symptomatic improvement.
The acute haemodynamic effects of pirbuterol in 63 patients were to lower left ventricular filling pressure and systemic vascular resistance and increase cardiac index and stroke volume index. Heart rate and systolic and diastolic blood pressures were almost unchanged. Haemodynamic reassessment at three months in 29 patients showed continued haemodynamic improvement. There was no apparent relation between haemodynamic improvement and improvement in exercise duration and symptomatic status even when alterations in concomitant diuretic treatment were taken into account.
The overall finding of sustained effect in our group of patients is not in agreement with the findings of Colucci et al. 25 (Figs. 1 and  4) . Other investigators using different drugs'415 have also been unable to predict which patients would show a sustained benefit. Extrapolation from the acute haemodynamic response in the supine patient at rest appears to be of extremely limited value. Such simplistic attempts at the prediction of the effect of sustained treatment with a drug do not take into consideration the numerous factors which affect the long term response to treatment of patients with severe chronic heart failure.28 To regard patient deterioration with chronic treatment to be solely the result of drug tolerance is to oversimplify a complex problem. The underlying pathological process may be progressive, and in some patients apparent treatment failure will simply reflect the natural history of heart failure. The powerful neurohumoral homeostatic mechanisms, such as either the renin-angiotensin-aldosterone system or the sympathetic nervous system, may override the effects of vasodilator drugs. The distribution of blood flow may be altered unfavourably by vasodilators.
This study shows that clinical and haemodynamic benefit is maintained long term in a substantial proportion of patients with severe chronic heart failure when treated with pirbuterol. Lack of sustained benefit in some patients may be the result of loss of drug effect, the natural history of disease, or other factors. The reasons for individual variation in response to pirbuterol need to be elucidated, just as they do with any drug. To answer the question of whether the natural history of heart failure can be altered in heterogeneous groups of patients with heart failure requires a large double blind placebo controlled trial. A rational basis for the selection of individual patients who would benefit from treatment remains a challenge.
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